Xspray Pharma publishes Interim Report Q2, January – June 2019
August 29, 2019 ”We have previously shown that it is possible to manufacture small pilot quantities of amorphous material for clinical studies but now we have shown that the process works at commercial scale. We have ”cracked the code”, so to speak, and have taken a great step toward a finished product.” Per Andersson, CEO […]
Read moreXspray Pharma publishes Interim Report Q1, January-March 2019
May 16, 2019 ”Over the past year, we’ve tripled the number of employees and I’m very pleased to see that our entire team is performing high quality work with great commitment. Xspray is today a company well-equipped to take a drug all the way to a finished product.” Per Andersson, CEO Xspray Pharma AB (publ) […]
Read moreXspray Pharma publishes its Year-end Report, January – December 2018
”Following determined efforts, we demonstrated performance in 2018 that has brought us significantly closer to a market launch of HyNap-Dasa and have thus increased Xspray’s possibilities of building shareholder value.” Per Andersson, CEO Xspray Pharma AB (publ) Fourth quarter, October – December 2018, parent company Amounts in brackets refer to the corresponding period for the […]
Read more